Theravance Biopharma Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 20, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	846	447	506	706	716	929
Market Cap Growth	84.30%	-11.74%	-28.28%	-1.40%	-22.96%	-29.02%
Enterprise Value	601	402	431	299	1,116	1,143
Last Close Price	16.30	9.10	10.20	10.40	9.30	14.40
PE Ratio	33.81	-	-	0.87	-	-
PS Ratio	12.35	7.19	9.75	14.70	14.72	15.82
PB Ratio	4.26	2.64	2.63	1.71	-2.40	-3.74
P/TBV Ratio	4.26	2.64	2.63	1.71	-	-
EV/Sales Ratio	8.82	6.47	8.30	6.23	22.95	19.46
Debt / Equity Ratio	0.19	0.28	0.23	0.12	-1.98	-2.23
Net Debt / Equity Ratio	-1.24	-0.22	-0.25	-0.62	-1.46	-1.26
Net Debt / EBITDA Ratio	9.24	0.95	1.03	3.62	-2.13	-1.30
Net Debt / FCF Ratio	-1.18	3.25	1.81	1.47	-2.35	-1.49
Asset Turnover	0.21	0.18	0.12	0.11	0.13	0.16
Quick Ratio	9.30	4.89	4.84	11.99	3.20	2.93
Current Ratio	9.48	5.02	5.39	12.31	4.26	3.18
Return on Equity (ROE)	14.03%	-29.04%	-16.86%	-179.84%	-	-
Return on Assets (ROA)	-5.32%	-7.21%	-6.78%	-10.07%	-35.20%	-42.38%
Return on Capital Employed (ROCE)	-8.70%	-13.20%	-15.00%	-13.70%	-75.10%	-86.10%
Earnings Yield	2.96%	-12.19%	-9.86%	115.58%	-24.49%	-24.45%
FCF Yield	24.54%	-2.56%	-5.27%	-24.86%	-25.94%	-22.61%
Buyback Yield / Dilution	-3.49%	11.67%	24.85%	-5.95%	-11.41%	-12.11%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.